S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ORIC · Oric Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Oric Pharmaceuticals Inc (ORIC)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$13.86
+0.07
(+0.54%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$13.86
$13.77
$14.20
52-WEEK RANGE
$13.86
$7.23
$14.68
What's happening
- ORIC is up 0.54% today, trading at $13.86. — Live quote
- Volume today (119,251) is well below its 3-month average of 1,535,850. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.38 actual vs. $-0.37 estimated (-3.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 10
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (21 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ORIC
+68.46%
vs S&P 500
+55.68%
1-YEAR RETURN
ORIC
+11.31%
vs S&P 500
-3.25%
6-MONTH RETURN
ORIC
+34.70%
3-MONTH RETURN
ORIC
+27.24%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.38
Est. $-0.37
MISS -3.1%
2026-04-26 (Q1 2026)
$-0.34
Est. $-0.33
MISS -2.7%
2026-01-26 (Q4 2025)
$-0.30
Est. $-0.37
BEAT +19.2%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.41
BEAT +20.1%
Valuation Measures & Ratios
Enterprise Value4$1.39B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.94
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-35.35%
Return on Assets (ROA9)-33.39%
Avg Volume (3M)1,535,850
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.18B | $1.33B | $1.19B | $782.0M | $398.1M |
| P/E | -8.10 | -9.88 | -8.88 | -5.88 | -3.28 |
| Price/Book | 3.11 | 3.20 | 2.91 | 2.41 | 1.81 |
| ROE | -38.35% | -32.42% | -32.81% | -41.02% | -55.32% |
| ROA | -36.13% | -30.85% | -30.97% | -38.32% | -50.05% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short16,315,970
Change from Prior Settlement-6.94%
% of Float—
Days to Cover (Short Ratio)9.85
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +11.3%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ORIC
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$45.3M | -$39.6M | -$36.7M | -$39.1M | -$32.7M | -$38.3M | -$36.0M | -$29.0M |
| Net income | -$41.5M | -$35.8M | -$32.6M | -$36.4M | -$30.0M | -$34.6M | -$32.0M | -$25.0M |
| EPS (diluted) | $-0.38 | $-0.34 | $-0.33 | $-0.47 | $-0.42 | $-0.49 | $-0.45 | $-0.37 |
| EPS (basic) | $-0.38 | $-0.34 | $-0.33 | $-0.47 | $-0.42 | $-0.49 | $-0.45 | $-0.37 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $404.7M | $436.8M | $408.9M | $431.2M | $346.9M | $242.9M | $274.1M | $302.1M |
| Total liabilities | $23.4M | $21.2M | $24.5M | $24.3M | $22.9M | $23.1M | $31.0M | $28.1M |
| Stockholders' equity | $381.3M | $415.6M | $384.4M | $406.9M | $324.0M | $219.7M | $243.1M | $274.0M |
| Total current assets | $273.7M | $290.2M | $288.5M | $295.6M | $291.1M | $211.4M | $262.2M | $279.4M |
| Total current liabilities | $20.8M | $17.8M | $20.4M | $20.2M | $18.1M | $17.6M | $24.8M | $21.2M |
| Cash & equivalents | $37.5M | $56.4M | $45.7M | $49.7M | $75.9M | $49.3M | $59.4M | $44.2M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $2.2M | $2.1M | $2.4M | $2.6M | $2.8M | $3.0M | $2.9M | $3.1M |
| Other non-current assets | $5.9M | $6.6M | $7.2M | $7.1M | $7.8M | $8.4M | $9.0M | $9.6M |
| Accounts payable | $3.9M | $2.9M | $3.8M | $2.9M | $3.1M | $5.2M | $1.5M | $4.2M |
| Accrued liabilities | $16.9M | $14.9M | $16.6M | $17.3M | $14.9M | $12.5M | $23.3M | $17.0M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $2.7M | $3.4M | $4.1M | $4.1M | $4.8M | $5.5M | $6.2M | $6.8M |
| Common stock & paid-in capital | $11.0K | $11.0K | $11.0K | $11.0K | $9.0K | $7.0K | $7.0K | $7.0K |
| Retained earnings | -$769.5M | -$728.0M | -$692.2M | -$661.7M | -$629.1M | -$592.8M | -$562.8M | -$526.5M |
| Accumulated other comprehensive income (loss) | -$1.0M | -$290.0K | $786.0K | $615.0K | $187.0K | $209.0K | $379.0K | $722.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.6M | -$32.4M | -$22.5M | -$25.1M | -$30.8M | -$32.5M | -$28.1M | -$28.8M |
| Investing cash flow | $11.9M | -$18.0M | $17.0M | -$110.5M | -$76.9M | $22.4M | $42.7M | $23.1M |
| Financing cash flow | $828.0K | $61.1M | $1.5M | $109.5M | $134.3M | $11.0K | $575.0K | $126.0K |
| Free cash flow | -$32.0M | -$32.4M | -$22.7M | -$25.1M | -$30.9M | -$32.9M | -$28.3M | -$29.2M |
| Capital expenditures | $356.0K | $2.0K | $227.0K | $35.0K | $63.0K | $387.0K | $219.0K | $418.0K |
| Share-based compensation | $7.1M | $6.9M | $6.3M | $5.6M | $6.6M | $6.6M | $5.2M | $5.1M |
| Purchases of investments | $47.8M | $78.0M | $45.3M | $165.5M | $124.4M | $64.7M | $34.6M | $54.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M |
| EPS (diluted) | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 |
| EPS (basic) | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M |
| Stockholders' equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M |
| Total current assets | $288.5M | $262.2M | $212.6M | $210.5M | $240.5M |
| Total current liabilities | $20.4M | $24.8M | $20.5M | $15.4M | $15.2M |
| Cash & equivalents | $45.7M | $59.4M | $23.4M | $66.8M | $226.0M |
| Marketable securities (current) | — | — | — | — | — |
| Property, plant & equipment | $2.4M | $2.9M | $2.9M | $3.3M | $2.4M |
| Other non-current assets | $7.2M | $9.0M | $9.7M | $11.5M | $12.3M |
| Accounts payable | $3.8M | $1.5M | $944.0K | $1.3M | $1.9M |
| Accrued liabilities | $16.6M | $23.3M | $19.5M | $14.1M | $13.3M |
| Long-term debt | — | — | — | — | $10.5M |
| Other non-current liabilities | $4.1M | $6.2M | $7.5M | $9.4M | $10.5M |
| Common stock & paid-in capital | $11.0K | $7.0K | $6.0K | $5.0K | $4.0K |
| Retained earnings | -$692.2M | -$562.8M | -$434.9M | -$334.2M | -$245.1M |
| Accumulated other comprehensive income (loss) | $786.0K | $379.0K | $258.0K | -$1.3M | -$103.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M |
| Investing cash flow | -$148.0M | $22.1M | -$43.4M | -$109.2M | $158.4M |
| Financing cash flow | $245.3M | $126.5M | $85.7M | $25.2M | $49.1M |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M |
| Capital expenditures | $712.0K | $1.2M | $849.0K | $2.1M | $939.0K |
| Share-based compensation | $25.0M | $20.2M | $15.2M | $14.5M | $12.9M |
| Purchases of investments | $399.8M | $251.9M | $239.2M | $238.1M | $69.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ORIC as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers91.2%
Shares Outstanding108,012,388
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Nextech Invest Ltd. | 7,162,637 | $77.6M | 6.63% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 6,815,875 | $73.8M | 6.31% | +14.0% | 2026-08-07 |
| EcoR1 Capital, LLC | 6,728,116 | $72.9M | 6.23% | +0.0% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6,617,554 | $71.7K | 6.13% | +22.8% | 2026-08-14 |
| VIKING GLOBAL INVESTORS LP | 5,126,762 | $55.5M | 4.75% | -12.0% | 2026-08-14 |
| State Street Corp | 4,894,000 | $53.0M | 4.53% | +32.2% | 2026-08-07 |
| SR ONE CAPITAL MANAGEMENT, LP | 4,615,384 | $50.0M | 4.27% | +2.2% | 2026-08-12 |
| Venrock Adviser, LLC | 4,319,765 | $46.8M | 4.00% | +0.0% | 2026-08-14 |
| NEA Management Company, LLC | 4,118,621 | $44.6M | 3.81% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,951,169 | $42.8M | 3.66% | +7.2% | 2026-06-30 |
| AIHC Capital Management Ltd | 3,828,460 | $41.5M | 3.54% | +55.7% | 2026-08-13 |
| ALKEON CAPITAL MANAGEMENT LLC | 3,739,096 | $40.5M | 3.46% | -17.0% | 2026-08-13 |
| Column Group LLC | 3,540,777 | $38.3M | 3.28% | +0.0% | 2026-08-14 |
| Siren, L.L.C. | 2,998,192 | $32.5M | 2.78% | +0.0% | 2026-08-13 |
| FMR LLC | 2,635,475 | $28.5M | 2.44% | +8.3% | 2026-08-13 |
| CITADEL ADVISORS LLC | 2,595,299 | $28.1M | 2.40% | +7.1% | 2026-08-14 |
| Goldman Sachs Group Inc | 2,451,796 | $26.6M | 2.27% | +66.1% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,090,089 | $22.6M | 1.94% | +13.7% | 2026-08-12 |
| First Turn Management, LLC | 2,017,284 | $21.8M | 1.87% | +0.0% | 2026-08-14 |
| ORBIMED ADVISORS LLC | 2,015,000 | $21.8M | 1.87% | -25.2% | 2026-08-14 |
| Integral Health Asset Management, LLC | 1,900,000 | $20.6M | 1.76% | +35.7% | 2026-08-14 |
| MPM BioImpact LLC | 1,882,162 | $20.4M | 1.74% | +4.3% | 2026-08-14 |
| Vivo Capital, LLC | 1,848,786 | $20.0M | 1.71% | +0.0% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 1,801,399 | $19.5M | 1.67% | +22.4% | 2026-08-11 |
| Franklin Templeton Inc | 1,797,377 | $19.5M | 1.66% | +23.7% | 2026-08-04 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-10-03 to 2026-10-20
Recent transactions
- Insiders have net sold 125,100 shares over the last 182 days, across 0 purchases and 10 sales.
- Most recent: Piscitelli Dominic (Chief Financial Officer) — Option exercise of 14,000 shares on 2026-10-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)125,100 sh(10 txns)
Net Shares-125,100
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer | Option exercise | 2026-10-20 | 14,000 |
| Heyman Richard A. | Reporting person | Option exercise | 2026-10-01 | 3,500 |
| Multani Pratik S | Chief Medical Officer | Open market sale | 2025-12-16 | 10,720 |
| Chacko Jacob | PRESIDENT AND CEO | Open market sale | 2025-12-16 | 33,374 |
| Kunkel Lori Anne | Reporting person | Option exercise | 2025-12-08 | 10,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-20 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 14,000 | $4.36 |
| 2026-10-20 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 14,000 | $13.53 |
| 2026-10-01 | Heyman Richard A. | Reporting person | Option exercise | 3,500 | $1.60 |
| 2026-10-01 | Heyman Richard A. | Reporting person | Open market sale | 3,500 | $12.91 |
| 2026-10-01 | Heyman Richard A. | Reporting person | Open market sale | 3,200 | $12.91 |
| 2026-09-28 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 13,400 | $4.36 |
| 2026-09-28 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 13,400 | $13.53 |
| 2026-09-24 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 600 | $4.36 |
| 2026-09-24 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 100 | $13.50 |
| 2026-09-24 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 500 | $13.51 |
| 2026-08-26 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 52,000 | $4.36 |
| 2026-08-26 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 25,000 | $6.00 |
| 2026-08-26 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 77,000 | $13.69 |
| 2026-07-24 | Heyman Richard A. | Reporting person | Option exercise | 3,500 | $1.60 |
| 2026-07-24 | Heyman Richard A. | Reporting person | Open market sale | 7,000 | $12.02 |
| 2026-07-24 | Heyman Richard A. | Reporting person | Open market sale | 6,100 | $12.02 |
| 2026-07-06 | Heyman Richard A. | Reporting person | Open market sale | 300 | $12.00 |
| 2026-02-24 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 52,000 | $4.36 |
| 2026-02-24 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 52,000 | $13.51 |
| 2026-01-16 | Heyman Richard A. | Reporting person | Open market sale | 3,500 | $12.00 |
| 2026-01-16 | Heyman Richard A. | Reporting person | Open market sale | 3,200 | $12.00 |
| 2025-12-16 | Multani Pratik S | Chief Medical Officer | Open market sale | 10,720 | $9.06 |
| 2025-12-16 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 10,720 | $9.06 |
| 2025-12-16 | Chacko Jacob | PRESIDENT AND CEO | Open market sale | 33,374 | $9.06 |
| 2025-12-15 | Multani Pratik S | Chief Medical Officer | Option exercise | 29,333 | $0.00 |
| 2025-12-15 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 29,333 | $0.00 |
| 2025-12-15 | Chacko Jacob | PRESIDENT AND CEO | Option exercise | 83,666 | $0.00 |
| 2025-12-08 | Kunkel Lori Anne | Reporting person | Option exercise | 10,000 | $7.90 |
| 2025-12-04 | Kunkel Lori Anne | Reporting person | Option exercise | 5,534 | $3.75 |
| 2025-10-06 | Piscitelli Dominic | Chief Financial Officer | Option exercise | 11,000 | $4.36 |
| 2025-10-06 | Piscitelli Dominic | Chief Financial Officer | Open market sale | 11,000 | $14.52 |
| 2025-10-06 | Chacko Jacob | PRESIDENT AND CEO | Open market sale | 37,461 | $12.32 |
| 2025-10-03 | Heyman Richard A. | Reporting person | Option exercise | 31,353 | $1.60 |
| 2025-10-03 | Heyman Richard A. | Reporting person | Option exercise | 1,447 | $3.75 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:54 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 4 | 2026-10-20 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-03 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-24 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-18 | View on SEC.gov → |
| 2026-05-04 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about ORIC (Oric Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company Stock
MarketBeat · 2026-10-21 -
Form 4 Oric Pharmaceuticals Inc: Dominic Piscitelli (CFO) For: 20 October
Investing.com UK · 2026-10-21 -
Oric Pharma CFO Dominic Piscitelli sells $189,390 in stock By Investing.com
Investing.com UK · 2026-10-21 -
Oric Pharmaceuticals (ORIC) CFO exercises 14,000 options and sells shares under a trading plan.
Stock Titan · 2026-10-21 -
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history
Yahoo Finance Singapore · 2026-10-21 -
ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026
Yahoo · 2026-10-21 -
ORIC Pharmaceuticals stock gains 12.10 percent at EUR 12.32
AD HOC NEWS · 2026-10-20 -
ORIC Pharmaceuticals, Inc. (ORIC) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20
No headlines in this category right now — try “All”.